Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations.
暂无分享,去创建一个
L E Friberg | M J E Brill | A N Kristoffersson | C Zhao | E I Nielsen | E. Nielsen | L. Friberg | A. Kristoffersson | M. J. Brill | C. Zhao | C. Zhao
[1] France Mentré,et al. Are Population Pharmacokinetic and/ or Pharmacodynamic Models Adequately Evaluated? , 2007, Clinical pharmacokinetics.
[2] B. Meibohm,et al. Translational PK/PD of anti-infective therapeutics. , 2016, Drug discovery today. Technologies.
[3] D. Mager,et al. Systems Pharmacology and Pharmacodynamics , 2016, AAPS Advances in the Pharmaceutical Sciences Series.
[4] G. Drusano. Pharmacokinetics and pharmacodynamics of antimicrobials. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] M. Neely,et al. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. , 2011, Current pharmaceutical biotechnology.
[6] Pranita D. Tamma,et al. Combination Therapy for Treatment of Infections with Gram-Negative Bacteria , 2012, Clinical Microbiology Reviews.
[7] D. Eleveld,et al. What about confidence intervals? A word of caution when interpreting PTA simulations. , 2016, The Journal of antimicrobial chemotherapy.
[8] W. Huisinga,et al. Translational Pharmacometric Evaluation of Typical Antibiotic Broad‐Spectrum Combination Therapies Against Staphylococcus Aureus Exploiting In Vitro Information , 2017, CPT: pharmacometrics & systems pharmacology.
[9] Ulrika S. H. Simonsson,et al. A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions , 2017, Nature Communications.
[10] S. Wicha,et al. Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models , 2017, CPT: pharmacometrics & systems pharmacology.
[11] C. Landersdorfer,et al. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling , 2017, Antimicrobial Agents and Chemotherapy.
[12] W. Greco,et al. The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.
[13] H. Derendorf,et al. Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model. , 2015, International journal of antimicrobial agents.
[14] C. I. Bliss. THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .
[15] A. Schumitzky,et al. Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis , 2014, PloS one.
[16] O. Cars,et al. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model. , 2016, The Journal of antimicrobial chemotherapy.
[17] H. Derendorf,et al. Pharmacokinetics and pharmacodynamics in antibiotic dose optimization , 2016, Expert opinion on drug metabolism & toxicology.
[18] M. Karlsson,et al. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection , 2016, Journal of Pharmacokinetics and Pharmacodynamics.
[19] A. Kristoffersson. Study Design and Dose Regimen Evaluation of Antibiotics based on Pharmacokinetic and Pharmacodynamic Modelling , 2015 .
[20] Mickael Guedj,et al. Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.
[21] THT Nguyen,et al. Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics , 2017, CPT: pharmacometrics & systems pharmacology.
[22] Neang S. Ly,et al. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies. , 2016, The Journal of antimicrobial chemotherapy.
[23] Neang S. Ly,et al. Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa , 2016, Antimicrobial Agents and Chemotherapy.
[24] Lena E. Friberg,et al. Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization , 2011, Antimicrobial Agents and Chemotherapy.
[25] H. Derendorf,et al. Experimental design and modelling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[26] Neang S. Ly,et al. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. , 2015, The Journal of antimicrobial chemotherapy.
[27] C. Landersdorfer,et al. High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii , 2017, The Journal of antimicrobial chemotherapy.
[28] C. Landersdorfer,et al. Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant Acinetobacter baumannii , 2015, Antimicrobial Agents and Chemotherapy.
[29] C. Landersdorfer,et al. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling , 2016, Antimicrobial Agents and Chemotherapy.
[30] H. Derendorf,et al. Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms , 2017, CPT: pharmacometrics & systems pharmacology.
[31] Neang S. Ly,et al. Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design , 2013, Antimicrobial Agents and Chemotherapy.
[32] Lena E Friberg,et al. Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs , 2013, Pharmacological Reviews.